Tianjin TEDA Biomedical Engineering First Half 2024 Earnings: CN¥0.002 loss per share (vs CN¥0.006 loss in 1H 2023)

Simply Wall St · 09/01 01:17

Tianjin TEDA Biomedical Engineering (HKG:8189) First Half 2024 Results

Key Financial Results

  • Revenue: CN¥211.6m (up 14% from 1H 2023).
  • Net loss: CN¥4.12m (loss narrowed by 63% from 1H 2023).
  • CN¥0.002 loss per share (improved from CN¥0.006 loss in 1H 2023).
earnings-and-revenue-history
SEHK:8189 Earnings and Revenue History September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tianjin TEDA Biomedical Engineering shares are up 8.9% from a week ago.

Risk Analysis

Before you take the next step you should know about the 3 warning signs for Tianjin TEDA Biomedical Engineering (2 can't be ignored!) that we have uncovered.